Arthritis affects 53.2 million Americans, representing a fifth of the country’s adult population. Globally, observers have projected that the condition will affect roughly one billion people by 2050. In recent years, arthritis research has yielded innovations that may counter the upward trend.
Certain studies have hinted at the potential efficacy of regenerative medicine in arthritis treatment. In 2023, a group of Europe-based medical researchers released a study on the impact of regenerative stem cells on knee arthritis. After fifteen months of observing 102 patients, the study found the cell injections efficacious in reducing pain. A consensus on the clinical application of regenerative medicine is pending.
Joint injections have found widespread acceptance in arthritis treatment, especially for rheumatoid arthritis patients. The injections give faster relief, less discomfort, and fewer complications. Alternatively, arthritis patients may receive the biological contents of the injections as pills. Infliximab and Etanercept are notable medications that rheumatoid and psoriatic arthritis patients receive via injections and pills.
Ellen Scharaga 